Indaptus Therapeutics, Inc. (INDP) 股票分析

公司概述

Indaptus Therapeutics, Inc. operates as a clinical biotechnology firm dedicated to the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate being Decoy20 designed for single agent or combination therapy-based durable responses. The company functions within the healthcare sector and specifically the biotechnology industry, positioning itself to leverage advancements in immunological science to address significant therapeutic needs in oncology and viral infections. As of the latest data, Indaptus holds a market capitalization of $4.15M and maintains a minimal workforce of 5 employees, while its annual revenue is not available for reporting in the current period. This market cap figure, combined with the absence of reported revenue, indicates that the company is in an early-stage development phase where capital allocation is focused on clinical progression rather than commercial sales or large-scale operational scaling. The extremely small employee base relative to the healthcare industry norm suggests a lean operational structure typical of pre-revenue biotechnology entities that rely heavily on external funding and intellectual property assets.

财务健康

The company reports a net income of $-20,848,916 over the trailing twelve months, while its EBITDA stands at $-19,832,778, and revenue is not available for the trailing twelve-month period. The substantial negative net income alongside the reported EBITDA gap reveals a cost structure dominated by high research and development expenditures and operational burn that exceed any current commercial revenue generation. Indaptus generates a free cash flow of $-8,159,969, which indicates that the company is currently consuming cash reserves to fund its clinical trials and operational expenses, limiting its immediate financial flexibility without further capital raising. The gross margin is recorded at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, collectively indicating that the company has not yet achieved commercial profitability or scaled sales sufficient to cover costs at a margin level. In terms of liquidity, the company holds $8.51M in cash against $0 in debt, resulting in a debt-to-equity ratio that is not available due to the lack of equity value in the traditional sense, yet the absence of debt suggests a conservative balance sheet regarding leverage. The current ratio stands at 1.51, which indicates that the company possesses 1.51 times more current assets than current liabilities, providing a moderate buffer for short-term obligations despite the ongoing cash burn. Return on Equity is reported at -587.6% and Return on Assets is -148.9%, metrics that reveal significant losses relative to the company's equity and asset base, highlighting the challenges in generating returns during the clinical development stage.

估值评估

The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is calculated at -1.33, implying that the market anticipates continued negative earnings or a significant turnaround in profitability is not immediately priced in. The price-to-book ratio is 1.28, suggesting that the market values the company at a slight premium of 28% over its book value, which often reflects the potential value of intangible assets like clinical pipeline data and intellectual property rather than tangible assets. The price-to-sales ratio is not available given the lack of revenue data, and the EV/EBITDA stands at 0.22, which is a very low multiple often seen in distressed or pre-revenue biotech companies where enterprise value is minimal relative to earnings before interest, taxes, depreciation, and amortization. The 52-week high is $19.91 and the 52-week low is $1.51, meaning the current trading price sits significantly below the annual peak but well above the annual trough, reflecting high volatility and sentiment-driven price action common in small-cap biotechnology stocks. The beta value is 0.99, indicating that the stock's price volatility moves in line with the broader market, suggesting that Indaptus does not exhibit extreme idiosyncratic risk compared to the overall market index.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue due to the absence of positive revenue figures to establish a baseline for growth analysis. As a non-dividend payer, Indaptus does not distribute a dividend yield or a payout ratio, which implies that the company retains all available cash to reinvest into its clinical development pipeline and operational growth rather than returning capital to shareholders. The absence of a dividend yield and the reported profit margin of 0.0% confirm that the company prioritizes capital expenditure for research and development over income distribution to investors. In summary, the overall growth and income profile is characterized by a lack of historical revenue growth data, zero dividend income, and a reliance on cash reserves to fuel future clinical milestones rather than current profitability or shareholder returns.